John Mascarenhas

John Mascarenhas

Company: Mount Sinai School of Medicine

Job title: Associate Professor

Bio:

Dr. John Mascarenhas is an Associate Professor of Medicine at the Icahn School of Medicine at Mount Sinai (ISMMS) and a member of the Tisch Cancer Institute. Dr. Mascarenhas is the Director of the Adult Leukemia Program and Leader of Clinical Investigation within the Myeloproliferative Disorders Program at Mount Sinai, under the direction of Dr. Ronald Hoffman. As a clinical investigator in malignant hematology with a focus in translational research involving myeloproliferative neoplasms (MPNs) and evolution to acute myeloid leukemia (AML), he is focused on the evaluation of rationale based novel therapies for patients with MPNs and AML. Dr. Mascarenhas is also the Principal Investigator (PI) of the clinical trials project within the National Cancer Institute sponsored Myeloproliferative Disorder Research Consortium (MPD-RC). He has served as PI or Study Chair of multiple investigator-initiated and industry-sponsored early and late phase clinical trials evaluating innovative approaches to the treatment of MPNs and AML. Additionally, he holds multiple administrative roles at Mount Sinai including Chair of the Leukemia Disease Management Team, Co-Chair of the Hematologic Malignancy Disease Focus Group, and full member of the Tisch Cancer Institute Protocol and Review Monitoring Committee.

Seminars:

Live Discussion & Question Time 12:00 pm

What are the clinical cross-learnings for JAK inhibitor application across both blood-related disorders and immune-mediated diseases? How can we refine clinical trial protocols to include clinically meaningful biomarkers with improved predictability of patient response and clinically meaningful endpoints? In what clinical indications do effective combination regimens that include JAK inhibitors play a role and how…Read more

day: Day One

Understanding JAK Inhibitor Treatment Strategies for Patients with Myeloproliferative Neoplasms 11:00 am

Rationale for JAK inhibition in MPN Success and limitations of JAK inhibitors in MPN Modern JAK inhibitor-based combination therapy approachesRead more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.